Biocardia Inc (BCDA) SEC 13F Holdings (Q2 2026): Institutional Buyers & Sellers

Medical device maker BioCardia put out a press release on August 24, 2026, announcing that the FDA has confirmed the meeting minutes for its Helix Transendocardial Delivery Catheter, which support a follow-on De Novo pre-submission for approval. In everyday terms: the company previously sat down with the FDA, and the agency has now signed off on the written record of that discussion — effectively paving the way for BioCardia to make its formal De Novo submission, the regulatory pathway used for novel medical devices. Keep in mind this 8-K merely 'furnishes' the press release for public reference (it's not a formally filed document), and the excerpt doesn't include any further detail beyond that.

On August 19, 2026, BioCardia (BCDA) got a warning letter from Nasdaq because its stock has closed below $1.00 per share for 30 consecutive business days, breaking the exchange's minimum bid price rule. The company now has 180 days — until February 16, 2027 — to get its closing bid back at $1.00 or higher for at least ten straight business days. Trading isn't affected for now, and if the deadline passes without compliance, BioCardia may qualify for a second 180-day window, though that route likely involves a reverse stock split.

AI summary pending